β-peptide lyotropic liquid crystals and methods of manufacture and use thereof
AssigneeWisconsin Alumni Research Foundation
InventorsSamuel H. Gellman, Nicholas L. Abbott, William C. Pomerantz
Life of this patent
Estimating the term…
Abstract
The present invention provides materials and methods that make liquid crystal phases accessible with relatively short β-peptides in aqueous solvents.
Claims20
A lyotropic liquid crystal comprising a β-peptide.
A lyotropic liquid crystal comprising a β-peptide and an aqueous solvent, wherein β-peptide forms a helix in the aqueous solvent, and wherein the β-peptide is globally amphiphilic.
A lyotropic liquid crystal comprising a β-peptide and an aqueous solvent, wherein the β-peptide forms a helix in the aqueous solvent, and wherein the β-peptide is globally non-amphiphilic.
A method of providing a β-peptide-based lyotropic liquid crystal, comprising the step of combining β-peptides capable of self-assembly under conditions to allow the self-assembly to occur whereby a β-peptide-based lyotropic liquid crystal is provided.
A liquid crystal device for detecting an analyte in a sample, comprising:
- (a) a sample chamber;
- and (b) a β-peptide-based lyotropic liquid crystal positioned within the sample chamber, wherein the β-peptide- based lyotropic liquid crystal comprises a β-peptide selected from the group consisting of:
- a β-peptide forming a globally amphiphilic helix;
- R-(ACHC-ACHC-β3-hLys)n wherein n is 2-4 and R is β3-hTyr or β3-h-para-Cl-Phe;
- β3-hTyr-(ACHC-ACHC-β3-hLys)2 or β3-hTyr-(ACHC-ACHC-β3-hLys)3;
- R-(ACHC-ACHC-β3-hLys)3 wherein R is β3-hTyr or β3-h- para-Cl-Phe and β3-hLys at position 10 is substituted by β3-hGlu;
- a β-peptide forming a globally non-amphiphilic helix;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC-ACHC-β3-hPhe-β3-hLys-NH2;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-X-ACHC-ACHC-β3-hPhe-β3-hLys-NH2 or β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β-hLys-ACHC-ACHC-β3-hPhe-X-NH2, wherein X is a hydrophilic amino acid;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-X-ACHC-ACHC-β3-hPhe-NH2 or β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC-ACHC-β3-hPhe-X—NH2, wherein X is β3-hGlu or β3-hGln;
- β3-hTyr-β3-hPhe-ACHC-β3-hLys-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC-ACHC-β3-hPhe-β3hLys-NH2;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC-β3-hLys-ACHC-NH2;
- CH3(CH2)nCONH-β3-hTyr-(ACHC-ACHC-β3-hLys)3 wherein n is 0-5;
- and
- biotin-β3-hGly-β3-hTyr-(ACHC-ACHC-β3-hLys)3.
A method of providing a network of self-assembled nanofibers, comprising the step of combining β-peptides capable of self-assembly under conditions to allow the self-assembly to occur whereby a network of self-assembled nanofibers is provided.
A lyotropic liquid crystal comprising a β-peptide, wherein the β-peptide is selected from the group consisting of:
- R-(ACHC-ACHC-β3-hLys)n wherein n is 2-4 and R is β3-hTyr or β3-h-para-Cl-Phe;
- β3-hTyr-(ACHC-ACHC-β3-hLys)2 or β3-hTyr-(ACHC-ACHC-β3-hLys)3;
- R-(ACHC-ACHC-β3-hLys)3 wherein R is β3-hTyr or β3-h-para-Cl-Phe and β3-hLys at position 10 is substituted by β3-hGlu;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC-ACHC-β3-hPhe-β3-hLys-NH2;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-X-ACHC-ACHC-β3-hPhe-β3-hLys-NH2 or β3- hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC-ACHC-β3-hPhe-X-NH2, wherein X is a hydrophilic amino acid;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-X-ACHC-ACHC-β3-hPhe-β3-hLys-NH2 or β3- hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-133-hLys-ACHC-ACHC-β3-hPhe-X-NH2, wherein X is β3-hGlu or β3-hGln;
- β3-hTyr-β3-hPhe-ACHC-β3-hLys-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-ACHC- ACHC-β3-hPhe-β3-hLys-NH2;
- β3-hTyr-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys-β3-hPhe-ACHC-β3-hPhe-β3-hLys- ACHC-β3-hLys-ACHC-NH2;
- CH3(CH2)nCONH-β3-hTyr-(ACHC-ACHC-β3-hLys)3 wherein n is 0-5;
- and
- biotin-β3-hGly-β3-hTyr-(ACHC-ACHC-β3-hLys)3.
Dependencies are inferred from the claim text.